URGNUroGen Pharma Ltd.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+12% of shares).
Choppy, but holding above its 200-day average. Oversold (RSI 22). Price is +26% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How URGN is trading
UroGen Pharma Ltd. is +105% over the past year while the S&P 500 is +18%: 87 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +26%
vs 200-day average · a clear uptrend
- RSI (14)
- 22
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 27%
Below its 52-week high
Details›
- Last close2026-10-09
- $36.82
- 1 monthS&P 500 +2.7%
- −13%
- 1 yearS&P 500 +18%
- +105%
- 5 yearsS&P 500 +88%
- +143%
- vs 50-day average$43.67
- −16%
- 52-week high
- $50.29
- 52-week low
- $16.42
- Annualised volatility
- 89%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$3.1M
| Year | Return |
|---|---|
| 2026 (year to date) | +57% |
| 2025 | +120% |
| 2024 | −29% |
| 2023 | +69% |
| 2022 | −6.7% |
| 2021 | −47% |
| 2020 | −46% |
| 2019 | −23% |
| 2018 | +16% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 9 | 5 of 9 | +3.2% |
| Feb | 9 | 3 of 9 | −3.4% |
| Mar | 9 | 3 of 9 | −2.8% |
| Apr | 9 | 5 of 9 | +7.9% |
| May | 9 | 3 of 9 | −10% |
| Jun | 10 | 8 of 10 | +32% |
| Jul | 10 | 5 of 10 | +13% |
| Aug | 10 | 6 of 10 | +3.3% |
| Sep | 10 | 3 of 10 | −4.8% |
| Oct | 10 | 5 of 10 | +1.1% |
| Nov | 9 | 6 of 9 | +9.6% |
| Dec | 9 | 3 of 9 | −7.4% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.